About NH HEALTH Company

In 2015, Nuohui Health was founded in Hangzhou, Zhejiang. It is the first biotech company in China to focus on early screening of high-incidence cancers at home. It is also the first leading industry to successfully list on the Hong Kong Stock Exchange, becoming the “first stock for early cancer screening in China”, with the stock code 6606.HK. With the mission of “changing the trajectory of life”, Nuohui Health adheres to the product concept of scientifically based, clinically proven, user needs, and promising markets, and invests heavily in self-developed multi-omics cancer screening technology innovation and product development. For colorectal cancer and stomach cancer, which are currently the most common digestive cancers in China, the company has separately marketed and commercialized three of the industry's first star products: Chang Wei Qing, Pop Tube, and Youyu Tube. Chang Weiqing is the first cancer screening product approved by the State Drug Administration in China. It is suitable for people aged 40-74 who are at high risk of colorectal cancer. Youyou tube is the first Helicobacter pylori consumer self-test product approved by the State Drug Administration in China. The Poop Tube is the first approved Fecal Occult Blood (FIT) home self-test device in China. In addition, the company has three clinical products that are being developed or are about to enter registered clinical products suitable for liver cancer (glycoside clearance), cervical cancer (uterine clearance), and nasopharyngeal cancer (Yi Biqing) screening pipeline products, as well as a number of other cancer screening pipeline products. The company holds global intellectual property rights for all of its listed and pipeline products. Based on the clinical market, Novartis Health Innovation has pioneered diversified business models in the early cancer screening industry, and has established extensive strategic cooperation with leading cross-border brands such as well-known medical examination chains, insurance companies, pharmacy chains and various Internet medical platforms. The company's main products have entered nearly 1,000 hospitals across the country, forming a closed-loop service for early screening, diagnosis and treatment combining outpatient and in-hospital physical examinations. Based on the domestic market, Novartis Health launched overseas market exploration in 2022. In June, Novartis Health joined hands with the US NASDAQ listed company Prenetics to launch Chang Weiqing in Hong Kong, China, and plans to gradually cover Macau and Taiwan in the future, thus entering the Southeast Asian market. At the same time, the company began construction of the first international R&D center located in the Hong Kong Science and Technology Park, focusing on multiomics R&D and product development, including second-generation sequencing technology (NGS). Novartis Health's listed company participated in the establishment of NHH Venture Fund (NHH Venture Fund) in August 2021 to focus on investing in breakthrough innovative molecular diagnostic technology for major human diseases. Up to now, the company has reached investment or strategic cooperation with five of the world's leading biotech companies for cancer screening or testing in the US, Germany, Switzerland and Singapore. Nuohui Health has 100,000-grade clean production workshops in Hangzhou that meet the international certification standards of ISO 13485 and ISO 9001, and also has third-party medical testing laboratories in Beijing, Hangzhou, and Guangzhou. The three laboratories have all obtained relevant international standard quality system certification and certification from the local Health and Health Commission and issued practice licenses.